CN117836013A - 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂 - Google Patents

结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂 Download PDF

Info

Publication number
CN117836013A
CN117836013A CN202280053524.XA CN202280053524A CN117836013A CN 117836013 A CN117836013 A CN 117836013A CN 202280053524 A CN202280053524 A CN 202280053524A CN 117836013 A CN117836013 A CN 117836013A
Authority
CN
China
Prior art keywords
conjugate
fap
acid
cancer
sifa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053524.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·拉赫曼
R·贝玖
G·梁
A·K·哈吉
C·巴尔内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Landy Diagnostics Co ltd
Original Assignee
Landy Diagnostics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landy Diagnostics Co ltd filed Critical Landy Diagnostics Co ltd
Publication of CN117836013A publication Critical patent/CN117836013A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202280053524.XA 2021-07-09 2022-07-08 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂 Pending CN117836013A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2109922.1 2021-07-09
GBGB2109922.1A GB202109922D0 (en) 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
PCT/US2022/073544 WO2023283627A1 (en) 2021-07-09 2022-07-08 Radiotracers and therapeutics binding to fibroblast activation protein (fap)

Publications (1)

Publication Number Publication Date
CN117836013A true CN117836013A (zh) 2024-04-05

Family

ID=77353994

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053524.XA Pending CN117836013A (zh) 2021-07-09 2022-07-08 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂

Country Status (7)

Country Link
US (1) US20240399001A1 (https=)
EP (1) EP4366786A1 (https=)
JP (1) JP2024529307A (https=)
KR (1) KR20240035488A (https=)
CN (1) CN117836013A (https=)
GB (1) GB202109922D0 (https=)
WO (1) WO2023283627A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024152775A1 (zh) * 2023-01-17 2024-07-25 云合智药（苏州）生物科技有限公司 缀合物、配体单元及其用途
WO2024227137A1 (en) * 2023-04-28 2024-10-31 The Board Of Regents Of The University Of Texas System Structurally-reinforced stable theranostic copper radiopharmaceuticals targeting fibroblast activation protein for cancer diagnosis and therapy
WO2025106926A1 (en) * 2023-11-16 2025-05-22 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
EP3749663A1 (en) 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство
JP7801207B2 (ja) 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途

Also Published As

Publication number Publication date
US20240399001A1 (en) 2024-12-05
WO2023283627A1 (en) 2023-01-12
JP2024529307A (ja) 2024-08-06
KR20240035488A (ko) 2024-03-15
EP4366786A1 (en) 2024-05-15
GB202109922D0 (en) 2021-08-25
WO2023283627A9 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
AU2019225154B2 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
CN117836013A (zh) 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂
CN115260160B (zh) 一种靶向成纤维细胞活化蛋白fap的化合物及其制备方法和应用
CN108541302B (zh) 用于成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂
KR20230165818A (ko) 섬유아세포 활성화 단백질 알파 및/또는 전립선-특이적 막 항원을 표적화하는 이종이가 및 동형이가 제제
TW201034689A (en) CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
CN115505032B (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用
CN118955616B (zh) 一种靶向结合成纤维细胞活化蛋白化合物及应用
KR20230118160A (ko) 섬유아세포 활성화 단백질 억제제
CN115010629B (zh) 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
CN119866334A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
CN116867520A (zh) 双模式放射性示踪剂和治疗剂
CN118126024B (zh) 一种全新骨架99mTc-FAPI诊断探针及其在制备诊断肿瘤的药物或试剂中的应用
CN116217505A (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
JP2026508513A (ja) 窒素含有複素環系化合物およびその製造方法と使用
KR20090130110A (ko) １８ｆ-표지된 폴레이트
CN117279930A (zh) 三官能化合物和其用途
JP2023521402A (ja) 医薬配合物
JP2024507343A (ja) デュアルモード放射性トレーサーおよびその療法
KR101861025B1 (ko) 영상화 제제로서의 ｎ-알콕시아미드 접합체
CN121909051A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
KR20260006628A (ko) 섬유아세포 활성화 단백질을 표적화하는 리간드
Singh et al. A homodimeric bivalent radioligand derived from 1-(2-methoxyphenyl) piperazine with high affinity for in vivo 5-HT1A receptor imaging
WO2024037635A1 (en) A trifunctional compound and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination